Home | News | Kontakt | Sitemap | Impressum

Medical > Therapy > Specific treatments

Prostanoids
Intravenous Iloprost

Epoprostenol can safely be replaced by intravenous iloprost (Higenbottam et al. 1998; Higenbottam et al. 1998), which is a prostacyclin analogue, which has several advantages over epoprostenol. While the latter has to be protected from light and needs to be dissolved in a glycine buffer for intravenous administration, iloprost is chemically much more stable. Moreover, iloprost has a biphasic disposition with longer half-lives of 3 to 4 min and 30 min, respectively, in contrast to a half-life of less than 5 min of epoprostenol (Krause et al. 1986). In addition, lower doses of iloprost might be needed for a comparable hemodynamic effect (Higenbottam et al. 1998). Beside ist successful use in IPAH (Higenbottam et al. 1998; Higenbottam et al. 1998; Hoeper et al. 2002), iloprost has been reported to be effective in scleroderma (de la Mata et al. 1994), primary antiphospholipid syndrome (de la Mata et al. 1994), portopulmonary hypertension (Hoeper et al. 2002), PAH associated with the toxic oil syndrome (Gomez-Sanchez et al. 1991) and CTEPH (Higenbottam et al. 1998).

References

Back to > Medical > Therapy > Specific treatments